08:55 AM EDT, 06/30/2025 (MT Newswires) -- AbbVie's ( ABBV ) Allergan Aesthetics unit said Monday that the US Food and Drug Administration has accepted for review the supplemental premarket approval application for Skinvive, an intradermal injection that improves facial skin smoothness.

The premarket approval application is supported by a clinical study that met all primary and secondary endpoints while assessing Skinvive in adults with neck lines seeking to improve their neck appearance, the company said.

Skinvive is an injectable version of hyaluronic acid which is a naturally occurring molecule found in the skin, and is currently approved in the U.S. to improve the smoothness of the cheeks in adults over the age of 21, the company said.